Investing.com - Financial Markets Worldwide

Novavax Inc (NVAX)

Symbol
Exchange
Currency
NVAX
NASDAQUSDReal-time
NVV1
TradeGateEURDelayed
92.33
-6.11(-6.21%)
-Closed.
Currency in USD
After Hours
93.75
+1.42(+1.54%)
- Real-time Data
  • Volume:
    5,972,577
  • Bid/Ask:
    93.50/93.75
  • Day's Range:
    91.70 - 103.57

NVAX Overview

Prev. Close
98.44
Day's Range
91.7-103.57
Revenue
1.2B
Open
100.15
52 wk Range
91.7-331
EPS
-14.82
Volume
5,972,577
Market Cap
6.98B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
6,258,650
P/E Ratio
-
Beta
1.31
1-Year Change
-27.87%
Shares Outstanding
75,608,073
Next Earnings Date
28 Feb 2022
What is your sentiment on Novavax Inc?
or
Market is currently closed. Voting is open during market hours.

Novavax Inc News

Novavax Inc Analysis

Novavax Inc Company Profile

Novavax Inc Company Profile

Industry
Biotechnology
Sector
Healthcare
Employees
792
Market
United States

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Read More

Income Statement

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
Airtel Africa
145.50147.20143.10-0.10-0.07%2.27MLondon
Barclays
206.95210.95206.35-2.85-1.36%63.30MLondon
BT Group
189.90191.25185.85+3.30+1.77%24.54MLondon
BP
394.10400.35388.70-1.65-0.42%49.31MLondon
Rio Tinto PLC
5,654.005,684.005,415.00+211.0+3.88%4.07MLondon
Polymetal
1,218.501,218.501,132.50+86.00+7.59%1.95MLondon
HSBC
512.50519.30510.50-3.50-0.68%38.17MLondon
IAG
160.00165.52157.86-5.64-3.40%25.56MLondon
Alphawave IP Group
174.50176.60156.40+10.90+6.66%1.56MLondon
Mast Energy Developments
6.756.756.75-0.35-4.93%1.72MLondon
Marks & Spencer
226.70229.80220.10+4.60+2.07%7.26MLondon
Prophotonix
8.758.758.750.0000.00%0.00London
Online Blockchain
44.0044.0044.00-0.50-1.12%77.71KLondon
Cenkos
81.0081.0081.000.000.00%33.92KLondon
ITM Power
312.60324.00312.00-16.40-4.99%3.40MLondon
  • Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
    0
    • Hopeless company
      3
      • will touch 230 today
        0
        • nova future dropping again.
          1
          • What’s happening. Good news drop. R&D director sells. Why not sack him
            0
            • Sure? is R&D director?
              0
          • Is the Politico reported legal securities law violation investigation into Novavax for real or a diversion tactic.As private investors we will never know but everything we read and know for certain about Novavax points to a health Company ready to take off.The current lows of down to $120 should be a fantastic buying opportunity. If not then credibility in all stock news reports will be shattered and a potential trigger for a market plunge.
            1
            • Purity is critical for vaccines
              0
              • Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing QualityOct 20, 2021
                0
                • strong sell now
                  1
                  • Why NVAX director sold around 26000 shares?
                    0
                    • to take profit. and buy in again at lower price.
                      0
                    • Directors cant just buy and sell as they feel like. So they have pre agreed trading plans. Its just tradhy journos writing rubbish articles to sppok investors.. only motive i can see. They ate probdbly in bed with short sellers. What they usually dont make clear is that when they sell stock they also iften purchase options at the same time.
                      1
                  • buy its jackpot time next stop 290
                    3
                    • If the vaccination route is overtaken by a single pill it will have a negative impact for NVAX and MRNA Assuming the pill is not FDA approved can see by year end NVAX breaking through $300.
                      0
                  • this gonna big 300 next stop
                    0
                    • Never lose faith in this stock. Gonna be the next big vax!
                      0
                      • surprise ... down for financial and another down on Monday I guess
                        2
                        • Why surprise ??
                          0
                      • surprise surprise... down for financials and another down on Monday I guess
                        0
                        • One of the best stocks to get.. Will easily rise to 300 with the EU deal.
                          2
                          • Modernas current market capitalisation is 10x that of Novavax.. inderatand they got a head start but given the results and based on the deal with EU, suggests filing for regulatory approval is imminent. Post approval novavax have a vaccine that is at least as good and also have a stage 3 flu vaccine as good or better than anything on the market. So combo flu / covid boosters = advantage novavax at current valuations.
                            1
                            • Novavax unable to get approval from any country so far. Only trials that say 90% effective but no approval as production process not ironed out. Q1 approval application delayed to Q3 already. 2021 sales of vaccine in doubt.
                              1
                              • They’ve already signed purchase agreement for 270 odd mllion in developed countries and over a billion for low and middle income. So not sure sales will be an issue.
                                0
                              • Not denying that they have orders but question is one of delivery. Maybe 2022 will be when they can start but till regulatory approvals start coming later this year, they remain behind the curve of other vax providers.
                                1
                            • NEJM.ORG announce Novax is safe !!
                              0
                              • Korea Drug and Food Safety official just before confirmed again they are now pre-reviewing the clinical trial data and will rapidly proceed the approval process as soon as SK Biosciense/NVAX submit their P3 approval documents regardless of the NVAX's filing plan in Q3 for FDA, MHRA and EMA.
                                0
                                • Korean government said this morning (May 12th in Korea time) they have no change with the existing rollout and admin plans of NVAX vaccine in Korea as Korean FDA is now reviewing the NVAX's clinical trial data submitted by SK Bioscience in parallel with and/or independent of FDA, MHRA and EMA.SK Biosciense now keeps their validation (It might seem to have been completed as they said last month their validation vaccine could be used for commercial purpose.) or commercial operation going and plans to commercially rollout 30m doses of the NVAX vaccine this year and another 10m doses in the early of next year to start to provide them to Korean government from June or July of this year. Korea Ministry of Food and Drug Safety is likely to approve the NVAX jab firstly in the world in next month as Korea President, Mr. Moon announced Monday (May 10) Korea government seems to move up their jab inoculation plan which is to achieve the herd immunity by November. It seems Korea government knows something that the US P3 results would NOT be different from the UK P3 results. Let's see what will happen soon....
                                  1
                                  • So is there an expectation on when they will approve?
                                    0
                                • dud
                                  1
                                  • Not sure how you work that out. Highest efficacy of all the vaccines against the original strain. Their technology also delivered the first malaria vaccine over 75 percent efficacy in a recent trial and its late stafe flu vaccine is as good or better than anything currently on the market. The only duds are the morons currently panic selling on the eve of approvals and a supply agreement with the EU.
                                    0
                                • the support is coming at 140
                                  2
                                  • Cant understand the selloff with approvals pending. Makes no sense.
                                    0
                                    • Guess the Company History with failed drug research does not help. However if they get FDA approval ( late April ?)they could soar to $400 plus.
                                      1
                                  • Court case. Great!
                                    0
                                    • Please clarify - what court case ?
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.